Results With HUMIRA in Children

With HUMIRA,

remission is possible for your child

With HUMIRA,
remission is possible for your child

Download the HUMIRA Pediatric IBD Brochure

You’ll find useful information about pediatric inflammatory bowel diseases (IBD), including ulcerative colitis, and how treatment with HUMIRA may help. Bring the brochure with you to discuss with the doctor at your child’s next appointment.


Results in as little as 8 weeks

The goal of pediatric ulcerative colitis (UC) treatment is remission—few or no symptoms. With HUMIRA, remission is possible for children 5 years of age and older.

A majority of patients achieved remission at 8 weeks

In a clinical study among pediatric patients from 5 to 17 years of age with moderate to severe ulcerative colitis, a majority of patients on HUMIRA achieved remission after just 8 weeks. Individual results may vary.

Many responding to treatment were in remission at 1 year

Many children who responded to treatment by week 8 were in remission at 1 year. Additionally, a majority of children responding by week 8 continued to have symptom relief at 1 year. Individual results may vary.

“Clinical remission is a key goal. For my moderate to severe UC patients, I look for treatment that is proven to achieve that goal rapidly.”

—Dr. Remo Panaccione

Director of the Inflammatory Bowel Disease Clinic and Professor of Medicine at University of Calgary


*Nurse Ambassadors are provided by AbbVie and do not work under the direction of your health care professional (HCP) or give medical advice. They are trained to direct patients to their HCP for treatment-related advice, including further referrals.